Is Trident Texofab overvalued or undervalued?

As of 18 November 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key ratios highlight this position, with a PE ratio of 174.34, an EV to EBITDA of 66.61, and a PEG ratio of 18.92, all suggesting that the stock is priced well above its earnings and growth potential.
In comparison to its peers, Trident Texofab's valuation appears excessive. For instance, Elitecon International has a PE ratio of 279.69, while PTC India, which is rated very attractive, has a PE of just 7.54. The stark contrast in these valuations underscores Trident Texofab's overvaluation. Additionally, while the stock has shown impressive returns over the past year, outperforming the Sensex significantly, the current valuation metrics suggest that investors may be paying too much for future growth prospects.